Download PDF
Horm Metab Res 2017; 49(08): 631-637
DOI: 10.1055/s-0043-110143
Endocrine Research
© Georg Thieme Verlag KG Stuttgart · New York

Suppression of Forkhead Box Protein O1 (FOXO1) Transcription Factor May Promote Adrenocortical Tumorigenesis

Adam Stenman
1   Yale Endocrine Neoplasia Laboratory, Yale School of Medicine, New Haven, Connecticut, USA
2   Department of Surgery, Yale School of Medicine, New Haven, Connecticut, USA
3   Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden
,
Timothy Murtha
1   Yale Endocrine Neoplasia Laboratory, Yale School of Medicine, New Haven, Connecticut, USA
2   Department of Surgery, Yale School of Medicine, New Haven, Connecticut, USA
,
Reju Korah
1   Yale Endocrine Neoplasia Laboratory, Yale School of Medicine, New Haven, Connecticut, USA
2   Department of Surgery, Yale School of Medicine, New Haven, Connecticut, USA
,
Tobias Carling
1   Yale Endocrine Neoplasia Laboratory, Yale School of Medicine, New Haven, Connecticut, USA
2   Department of Surgery, Yale School of Medicine, New Haven, Connecticut, USA
› Author Affiliations
Further Information

Publication History

received 31 March 2017

accepted 25 April 2017

Publication Date:
22 June 2017 (online)

Also available at
    Permissions and Reprints

Abstract

Despite recent comprehensive genetic analyses, molecular evidence for a pathophysiological continuum linking benign adrenocortical adenoma (ACA) and highly aggressive adrenocortical carcinoma (ACC) is still elusive. Using human tumor samples and the established ACC cell line SW-13, this study investigated potential regulatory roles for FOXO transcription factors, in modulating adrenocortical tumorigenesis. Adrenocortical tumor specimens (20 ACAs, 10 ACCs, and 9 normal adrenal tissue samples) obtained from 30 patients were analyzed for ubiquitously expressed FOXO transcription factors, FOXO1 and FOXO3 using qRT-PCR and immunohistochemistry. The SW-13 ACC cells were used to study the phenotypic effects of FOXO regulation in vitro. While FOXO3 expression remained unchanged in ACCs, FOXO1 expression was found to be significantly downregulated in 19/20 ACAs and 9/10 ACCs (p<0.0001 and p<0.05, respectively), suggesting a global role for FOXO1 suppression in promoting and maintaining adrenocortical dedifferentiation. Silencing of FOXO1 in SW-13 cells resulted in significant loss of viability (p<0.001) mediated by apoptosis as determined by quantitative Annexin V immunofluorescence analysis (p<0.01). FOXO1 silencing also augmented the migratory behavior of SW-13 cells (p<0.0001), suggesting distinct roles for FOXO1 in promoting viability and controlled motility of adrenocortical cells.

Key words

adrenal cortical adenoma - adrenocortical carcinoma - tumorigenesis - FOXO

Supporting Information

    Supporting Information for this article is available online at http://www.thieme-connect.de/products.
  • Supporting Information
 

  • References

  • 1 Mansmann G, Lau J, Balk E, Rothberg M, Miyachi Y, Bornstein SR. The clinically inapparent adrenal mass: Update in diagnosis and management. Endocr Rev 2004; 25: 309-340
    CrossrefPubMedGoogle Scholar
  • 2 Barzon L, Sonino N, Fallo F, Palu G, Boscaro M. Prevalence and natural history of adrenal incidentalomas. Eur J Endocrinol 2003; 149: 273-285
    CrossrefPubMedGoogle Scholar
  • 3 Else T, Kim AC, Sabolch A, Raymond VM, Kandathil A, Caoili EM, Jolly S, Miller BS, Giordano TJ, Hammer GD. Adrenocortical carcinoma. Endocr Rev 2014; 35: 282-326
    CrossrefPubMedGoogle Scholar
  • 4 Libé R. Adrenocortical carcinoma (ACC): Diagnosis, prognosis, and treatment. Front Cell Dev Biol 2015; 3: 45
    PubMedGoogle Scholar
  • 5 Wajchenberg BL, Albergaria Pereira MA, Medonca BB, Latronico AC, Campos Carneiro P, Alves VA, Zerbini MC, Liberman B, Carlos Gomes G, Kirschner MA. Adrenocortical carcinoma: Clinical and laboratory observations. Cancer 2000; 88: 711-736
    CrossrefPubMedGoogle Scholar
  • 6 Lebastchi AH, Kunstman JW, Carling T. Adrenocortical Carcinoma: Current Therapeutic State-of-the-Art. J Oncol 2012; 2012: 234726
    PubMedGoogle Scholar
  • 7 Liu T, Brown TC, Juhlin CC, Andreasson A, Wang N, Bäckdahl M, Healy JM, Prasad ML, Korah R, Carling T, Xu D, Larsson C. The activating TERT promoter mutation C228T is recurrent in subsets of adrenal tumors. Endocr Relat Cancer 2014; 21: 427-434
    CrossrefPubMedGoogle Scholar
  • 8 Horvath A, Boikos S, Giatzakis C, Robinson-White A, Groussin L, Griffin KJ, Stein E, Levine E, Delimpasi G, Hsiao HP, Keil M, Heyerdahl S, Matyakhina L, Libè R, Fratticci A, Kirschner LS, Cramer K, Gaillard RC, Bertagna X, Carney JA, Bertherat J, Bossis I, Stratakis CA. A genome-wide scan identifies mutations in the gene encoding phosphodiesterase 11A4 (PDE11A) in individuals with adrenocortical hyperplasia. Nat Genet 2006; 38: 794-800
    CrossrefPubMedGoogle Scholar
  • 9 Beuschlein F, Fassnacht M, Assié G, Calebiro D, Stratakis CA, Osswald A, Ronchi CL, Wieland T, Sbiera S, Faucz FR, Schaak K, Schmittfull A, Schwarzmayr T, Barreau O, Vezzosi D, Rizk-Rabin M, Zabel U, Szarek E, Salpea P, Forlino A, Vetro A, Zuffardi O, Kisker C, Diener S, Meitinger T, Lohse MJ, Reincke M, Bertherat J, Strom TM, Allolio B. Constitutive activation of PKA catalytic subunit in adrenal Cushing’s syndrome. N Engl J Med 2014; 370: 1019-1028
    CrossrefPubMedGoogle Scholar
  • 10 Goh G, Scholl UI, Healy JM, Choi M, Prasad ML, Nelson-Williams C, Kunstman JW, Korah R, Suttorp AC, Dietrich D, Haase M, Willenberg HS, Stålberg P, Hellman P, Akerström G, Björklund P, Carling T, Lifton RP. Recurrent activating mutation in PRKACA in cortisol-producing adrenal tumors. Nat Genet 2014; 46: 613-617
    CrossrefPubMedGoogle Scholar
  • 11 Choi M, Scholl UI, Yue P, Björklund P, Zhao B, Nelson-Williams C, Ji W, Cho Y, Patel A, Men CJ, Lolis E, Wisgerhof MV, Geller DS, Mane S, Hellman P, Westin G, Åkerström G, Wang W, Carling T. Lifton RP. K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. Science 2011; 331: 768-772
    CrossrefPubMedGoogle Scholar
  • 12 Libè R, Fratticci A, Bertherat J. Adrenocortical cancer: Pathophysiology and clinical management. Endocr Relat Cancer 2007; 14: 13-28
    CrossrefPubMedGoogle Scholar
  • 13 Parviainen H, Schrade A, Kiiveri S, Prunskaite-Hyyryläinen R, Haglund C, Vainio S, Wilson DB, Arola J, Heikinheimo M. Expression of Wnt and TGF-β pathway components and key adrenal transcription factors in adrenocortical tumors: Association to carcinoma aggressiveness. Pathol Res Pract 2013; 209: 503-509
    CrossrefPubMedGoogle Scholar
  • 14 Li FP, Fraumeni JF. Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann Intern Med 1969; 71: 747-752
    PubMedGoogle Scholar
  • 15 Assié G, Letouzé E, Fassnacht M, Jouinot A, Luscap W, Barreau O, Omeiri H, Rodriguez S, Perlemoine K, René-Corail F, Elarouci N, Sbiera S, Kroiss M, Allolio B, Waldmann J, Quinkler M, Mannelli M, Mantero F, Papathomas T, De Krijger R, Tabarin A, Kerlan V, Baudin E, Tissier F, Dousset B, Groussin L, Amar L, Clauser E, Bertagna X, Ragazzon B, Beuschlein F, Libé R, de Reyniès A, Bertherat J. Integrated genomic characterization of adrenocortical carcinoma. Nat Genet 2014; 46: 607-612
    CrossrefPubMedGoogle Scholar
  • 16 Juhlin CC, Goh G, Healy JM, Fonseca AL, Scholl UI, Stenman A, Kunstman JW, Brown TC, Overton JD, Mane SM, Nelson-Williams C, Bäckdahl M, Suttorp AC, Haase M, Choi M, Schlessinger J, Rimm DL, Höög A, Prasad ML, Korah R, Larsson C, Lifton RP, Carling T. Whole-exome sequencing characterizes the landscape of somatic mutations and copy number alterations in adrenocortical carcinoma. J Clin Endocrinol Metab 2015; 100: E493-E502
    CrossrefPubMedGoogle Scholar
  • 17 Beuschlein F, Looyenga BD, Reincke M, Hammer GD. Role of the inhibin/activin system and luteinizing hormone in adrenocortical tumorigenesis. Horm Metab Res 2004; 36: 392-396
    Article in Thieme ConnectPubMedGoogle Scholar
  • 18 van der Horst A, Burgering BM. Stressing the role of FoxO proteins in lifespan and disease. Nat Rev Mol Cell Biol 2007; 8: 440-450
    CrossrefPubMedGoogle Scholar
  • 19 Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ, Arden KC, Blenis J, Greenberg ME. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999; 96: 857-868
    CrossrefPubMedGoogle Scholar
  • 20 Seoane J, Le HV, Shen L, Anderson SA, Massagué J. Integration of Smad and forkhead pathways in the control of neuroepithelial and glioblastoma cell proliferation. Cell 2004; 117: 211-223
    CrossrefPubMedGoogle Scholar
  • 21 Naka K, Hoshii T, Muraguchi T, Tadokoro Y, Ooshio T, Kondo Y, Nakao S, Motoyama N, Hirao A. TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia. Nature 2010; 463: 676-680
    CrossrefPubMedGoogle Scholar
  • 22 Gomis RR, Alarcón C, Nadal C, Van Poznak C, Massagué J. C/EBPbeta at the core of the TGFbeta cytostatic response and its evasion in metastatic breast cancer cells. Cancer Cell 2006; 10: 203-214
    CrossrefPubMedGoogle Scholar
  • 23 Franz F, Weidinger C, Krause K, Gimm O, Dralle H, Führer D. The transcriptional regulation of foxo genes in thyrocytes. Horm Metab Res 2016; 48: 601-606
    Article in Thieme ConnectPubMedGoogle Scholar
  • 24 Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25: 402-408
    CrossrefPubMedGoogle Scholar
  • 25 Kunstman JW, Korah R, Healy JM, Prasad M, Carling T. Quantitative assessment of RASSF1A methylation as a putative molecular marker in papillary thyroid carcinoma. Surgery 2013; 154: 1255-1261
    CrossrefPubMedGoogle Scholar
  • 26 Korah R, Healy JM, Kunstman JW, Fonseca AL, Ameri AH, Prasad ML, Carling T. Epigenetic silencing of RASSF1A deregulates cytoskeleton and promotes malignant behavior of adrenocortical carcinoma. Mol Cancer 2013; 12: 87
    CrossrefPubMedGoogle Scholar
  • 27 Wang Y, Zhou Y, Graves DT. FOXO transcription factors: Their clinical significance and regulation. Biomed Res Int 2014; 925350
    PubMedGoogle Scholar
  • 28 Danesi R, Agen C, Bernardini N, Costa M, Del Tacca M. The antiproliferative effect of suramin on the cancer cell line SW-13 is mediated by the inhibition of transforming growth factor beta 1 (TGF-beta 1). Pharmacol Res 1992; 25 (Suppl. 01) 17-18
    PubMedGoogle Scholar
  • 29 Juhlin CC, Stenman A, Haglund F, Clark VE, Brown TC, Baranoski J, Bilguvar K, Goh G, Welander J, Svahn F, Rubinstein JC, Caramuta S, Yasuno K, Günel M, Bäckdahl M, Gimm O, Söderkvist P, Prasad ML, Korah R, Lifton RP, Carling T. Whole-exome sequencing defines the mutational landscape of pheochromocytoma and identifies KMT2D as a recurrently mutated gene. Genes Chromosomes Cancer 2015; 54: 542-554
    CrossrefPubMedGoogle Scholar
  • 30 van der Vos KE, Coffer PJ. The extending network of FOXO transcriptional target genes. Antioxid Redox Signal 2011; 14: 579-592
    CrossrefPubMedGoogle Scholar
  • 31 Remy I, Montmarquette A, Michnick SW. PKB/Akt modulates TGF-beta signalling through a direct interaction with Smad3. Nat Cell Biol 2004; 6: 358-365
    CrossrefPubMedGoogle Scholar
  • 32 Uhlén M, Fagerberg L, Hallström BM, Lindskog C, Oksvold P, Mardinoglu A, Sivertsson Å, Kampf C, Sjöstedt E, Asplund A, Olsson I, Edlund K, Lundberg E, Navani S, Szigyarto CA, Odeberg J, Djureinovic D, Takanen JO, Hober S, Alm T, Edqvist PH, Berling H, Tegel H, Mulder J, Rockberg J, Nilsson P, Schwenk JM, Hamsten M, von Feilitzen K, Forsberg M, Persson L, Johansson F, Zwahlen M, von Heijne G, Nielsen J, Pontén F. Proteomics. Tissue-based map of the human proteome. Science 2015; 347: 1260419
    CrossrefPubMedGoogle Scholar